Platelet Reactivity Clinical Trial
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Study
Ticagrelor has been demonstrated to provide a more rapid and more powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients. However, current guidelines recommend ticagrelor 90 mg twice daily might not be suitable for patients of Chinese. Therefore, the investigators performed this study to observe the efficacy of 60-mg ticagrelor in comparison to 75-mg clopidogrel in Chinese patients with stable CAD.
Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is the established
standard of care in ACS patients. Although a popular P2Y12 receptor inhibitor, clopidogrel is
not the most potent antiplatelet agent due to its metabolic activation. Metabolic activation
of clopidogrel depends on multiple cytochrome P450 (CYP) enzymes, including CYP2C19, which
can delay the onset of its activity; in addition, some populations carry a reduced-function
allele of the CYP2C19 gene. Notably, poor drug metabolism of clopidogrel is more common in
Asian populations compared with other international regions, due to the prevalence of CYP2C19
reduced-function alleles in these patients. A recent study indicated that Asians might have
different adverse event profiles (thrombophilia and bleeding) and "therapeutic window"
compared with white subjects, suggesting that regional differences may influence the altered
response of clopidogrel to the onset of thrombotic events.
Ticagrelor is an orally administered, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with ACS. Guidelines give a recommendation on the use of dual antiplatelet therapy (DAPT) support ticagrelor 90 mg twice daily over clopidogrel 75 mg daily in addition to aspirin in ACS patients with or without ST-segment elevation. Increasing evidence indicated that Asian patients showed higher active metabolite exposure rates and stronger pharmacodynamic responses than their Caucasian subjects when treated with the same oral doses of prasugrel .In Korea and Japan, it has been reported that low doses of ticagrelor might have a more potent inhibition of platelet aggregation (IPA) than clopidogrel in healthy subjects and patients with stable coronary artery disease, respectively .In our previous study, the investigators found that half-dose ticagrelor produced similar inhibitory effects on platelet aggregation as standard-dose ticagrelor and exerted significantly stronger effects than clopidogrel in patients with ACS and one-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than clopidogrel in patients with stable CAD. Furthermore, standard-dose ticagrelor (180mg loading dose [LD], then 90mg twice daily) has a significant increase in the risk of bleeding and incidence rate of dyspnea, and that higher discontinuation rates due to adverse effects compared to clopidogrel. A recent study demonstrated that maximum plasma concentration and area under the plasma concentration-time curve of ticagrelor (90 mg twice daily) and its active metabolite (AR-C124910XX) tended to be approximately 40% higher in healthy Chinese volunteers compared with Caucasian subjects. Notably, poor drug metabolism of clopidogrel is more common in Asian populations compared with other international regions, due to the prevalence of CYP2C19 reduced-function alleles. The data suggested that a low dose of ticagrelor might be more appropriate for Chinese patients.
The objectives of this study were to evaluate the effects of ticagrelor (60.0mg daily) in comparison to clopidogrel (75mg daily) on platelet reactivity in Chinese patients with stable CAD. ;
|Source||First Affiliated Hospital of Harbin Medical University|
|Contact||Yue Li, professor|
|Start date||August 29, 2018|
|Completion date||August 29, 2019|
|Not yet recruiting||
||Phase 2/Phase 3|